Intriguing research into stock market price trends shows that investors behave strangely when a stock trades close to its 52-week high... Despite flying high, holders of the shares are more likely to sell out and snatch a profit than h...
BML — Biomed Lublin Wytwornia Surowic i Szczepionek SA Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro CapSucker Stock
- PLN196.30m
- PLN183.32m
- PLN41.15m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.63 | ||
| Price to Tang. Book | 2.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.77 | ||
| EV to EBITDA | 14.7 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.22% | ||
| Return on Equity | 7.6% | ||
| Operating Margin | 17.48% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 31.4 | 32.29 | 39.11 | 40.16 | 41.15 | n/a | n/a | 2.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +82.08 | -1.47 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for BML
Anyone familiar with stock market screeners will know that shares in Biomed Lublin Wytwornia Surowic I Szczepionek Sa (WAR:BML) have been in an uptrend in recent months, with strong relative price strength on a 1-month, 6-month and 12-...
Anyone familiar with stock market screeners will know that shares in Biomed Lublin Wytwornia Surowic I Szczepionek Sa (WAR:BML) have been in an uptrend in recent months, with strong relative price strength on a 1-month, 6-month and 12-...
Profile Summary
Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company engaged in the pharmaceuticals industry.
Directors
- Jaroslaw Blaszczak CSU
- Piotr Fic CMG (52)
- Wiktor Napiora VSU (62)
- Katarzyna Krukowska CAO
- Waldemar Sierocki SEC (63)
- Konrad Miterski IND (47)
- Dirk Pamperin IND (52)
- Dariusz Kucowicz SUB (53)
- Piotr Kwasniewski SUB
- Last Annual
- December 31st, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- December 13th, 2010
- Public Since
- July 29th, 2011
- No. of Employees
- 223
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Warsaw Stock Exchange
- Shares in Issue
- 65,260,410
- Address
- ul. Uniwersytecka 10, LUBLIN, 20-029
- Web
- https://biomedlublin.com/
- Phone
- +48 815338221
- Auditors
- UHY ECA Audyt Sp. Zoo SP. k.
Upcoming Events for BML
Similar to BML
Bioceltix SA
Warsaw Stock Exchange
Biogened SA
Warsaw Stock Exchange
BioMaxima SA
Warsaw Stock Exchange
Cannabis Poland SA
Warsaw Stock Exchange
Celon Pharma SA
Warsaw Stock Exchange
FAQ
What is the Biomed Lublin Wytwornia Surowic i Szczepionek SA share price?
As of Today at 13:03 UTC, shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA are trading at PLN3.01. This share price information is delayed by 15 minutes.
How has the Biomed Lublin Wytwornia Surowic i Szczepionek SA share price performed this year?
Shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA last closed at PLN3.01 and the price had moved by -69.7% over the past 365 days. In terms of relative price strength the Biomed Lublin Wytwornia Surowic i Szczepionek SA share price has underperformed the FTSE Global All Cap Index by -66.7% over the past year.
What are the analyst and broker recommendations for Biomed Lublin Wytwornia Surowic i Szczepionek SA?
There is no consensus recommendation for this security.
What is the Biomed Lublin Wytwornia Surowic i Szczepionek SA dividend yield?
Biomed Lublin Wytwornia Surowic i Szczepionek SA does not currently pay a dividend.
Does Biomed Lublin Wytwornia Surowic i Szczepionek SA pay a dividend?
Biomed Lublin Wytwornia Surowic i Szczepionek SA does not currently pay a dividend.
When does Biomed Lublin Wytwornia Surowic i Szczepionek SA next pay dividends?
Biomed Lublin Wytwornia Surowic i Szczepionek SA does not currently pay a dividend.
How do I buy Biomed Lublin Wytwornia Surowic i Szczepionek SA shares?
To buy shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biomed Lublin Wytwornia Surowic i Szczepionek SA?
As of the previous close price of PLN3.01, shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA had a market capitalisation of PLN196.30m.
Where are Biomed Lublin Wytwornia Surowic i Szczepionek SA shares listed?
Here are the trading details for Biomed Lublin Wytwornia Surowic i Szczepionek SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: BML
What kind of share is Biomed Lublin Wytwornia Surowic i Szczepionek SA?
Based on an overall assessment of its quality, value and momentum Biomed Lublin Wytwornia Surowic i Szczepionek SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biomed Lublin Wytwornia Surowic i Szczepionek SA share price forecast for 2022?
The analyst consensus target price for shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA is PLN10.80. That is 259.04% above the last closing price of PLN3.01.
Analysts covering Biomed Lublin Wytwornia Surowic i Szczepionek SA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
What is the trend in the Biomed Lublin Wytwornia Surowic i Szczepionek SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomed Lublin Wytwornia Surowic i Szczepionek SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -16.56%.
As of the last closing price of PLN3.01, shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA were trading -44.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biomed Lublin Wytwornia Surowic i Szczepionek SA PE Ratio?
The Biomed Lublin Wytwornia Surowic i Szczepionek SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN3.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biomed Lublin Wytwornia Surowic i Szczepionek SA?
Biomed Lublin Wytwornia Surowic i Szczepionek SA's management team is headed by:
- Jaroslaw Blaszczak - CSU
- Piotr Fic - CMG
- Wiktor Napiora - VSU
- Katarzyna Krukowska - CAO
- Waldemar Sierocki - SEC
- Konrad Miterski - IND
- Dirk Pamperin - IND
- Dariusz Kucowicz - SUB
- Piotr Kwasniewski - SUB